Gegründet: Januar 2009
Novel stent technologies to address and overcome clinical shortcomings.
Qvanteq develops novel stent technologies to address and overcome the clinically adverse effects of today’s available coronary artery stents. A coronary stent is a small (metal) mesh tube which is being implanted into coronary arteries to prevent heart attacks.
Qvanteq is a CTI start-up company and a spin-off from the Swiss Federal Institute of Technology (ETH) Zurich. The company was founded in early 2009 and is held by private investors. Its Headquarter is located at Technopark in Zurich, Switzerland.
Milestones / News
|Dieses Profil mit anderen teilen|